{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Subjects&page=26", "query": { "condition": "Normal Subjects", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 2506, "total_pages": 251, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Subjects&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Subjects&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T08:16:50.181Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04198766", "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non-Small Cell Lung Cancer", "Head and Neck Cancer", "Melanoma", "Gastric Cancer", "Renal Cell Carcinoma", "Urothelial Carcinoma", "Resectable Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "INBRX-106 - Hexavalent OX40 agonist antibody", "type": "DRUG" }, { "name": "pembrolizumab 200 mg", "type": "DRUG" }, { "name": "pembrolizumab 400 mg", "type": "DRUG" }, { "name": "Carboplatin AUC-5", "type": "DRUG" }, { "name": "Carboplatin AUC-6", "type": "DRUG" }, { "name": "Pemetrexed 500 mg/m2", "type": "DRUG" }, { "name": "Cisplatin 75mg/m2", "type": "DRUG" }, { "name": "Paclitaxel 200mg/m2", "type": "DRUG" }, { "name": "Nab paclitaxel 100mg/m2", "type": "DRUG" }, { "name": "Gemcitabine (1000 mg/m2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inhibrx Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2019-12-10", "completion_date": "2033-07", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-28T08:16:50.181Z", "location_count": 30, "location_summary": "Duarte, California • Glendale, California • Los Angeles, California + 25 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Murrieta", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04198766" }, { "nct_id": "NCT00137969", "title": "A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 262, "start_date": "2005-05-10", "completion_date": "2008-08-25", "has_results": true, "last_update_posted_date": "2019-08-20", "last_synced_at": "2026-10-28T08:16:50.181Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00137969" }, { "nct_id": "NCT03454451", "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Renal Cell Cancer", "Colorectal Cancer", "Triple Negative Breast Cancer", "Cervical Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Endometrial Cancer", "Sarcoma", "Squamous Cell Carcinoma of the Head and Neck", "Bladder Cancer", "Metastatic Castration Resistant Prostate Cancer", "Non-hodgkin Lymphoma" ], "interventions": [ { "name": "CPI-006", "type": "DRUG" }, { "name": "CPI-006 + ciforadenant", "type": "DRUG" }, { "name": "CPI-006 + pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corvus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2018-04-25", "completion_date": "2023-02-19", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-10-28T08:16:50.181Z", "location_count": 22, "location_summary": "Tucson, Arizona • Duarte, California • San Francisco, California + 18 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03454451" }, { "nct_id": "NCT00752154", "title": "Curcumin in Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Curcumin (Longvida™)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2010-01", "completion_date": "2011-01-01", "has_results": false, "last_update_posted_date": "2023-09-29", "last_synced_at": "2026-10-28T08:16:50.181Z", "location_count": 2, "location_summary": "Beverly Hills, California • Los Angeles, California", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00752154" }, { "nct_id": "NCT04724369", "title": "Open-Label Study of 18F-mFBG for Imaging Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "18F-MFBG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 43, "start_date": "2021-11-18", "completion_date": "2026-08-30", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-28T08:16:50.181Z", "location_count": 8, "location_summary": "Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04724369" }, { "nct_id": "NCT01998984", "title": "Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Actinic Keratosis" ], "interventions": [ { "name": "ingenol mebutate", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 266, "start_date": "2014-01", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2025-03-10", "last_synced_at": "2026-10-28T08:16:50.181Z", "location_count": 1, "location_summary": "Smithtown, New York", "locations": [ { "city": "Smithtown", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01998984" }, { "nct_id": "NCT03875482", "title": "A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" }, { "name": "Placebo solution for risankizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 157, "start_date": "2019-05-13", "completion_date": "2020-07-15", "has_results": true, "last_update_posted_date": "2021-03-16", "last_synced_at": "2026-10-28T08:16:50.181Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03875482" }, { "nct_id": "NCT00169559", "title": "Dyslipidemia Study Investigating The Increase In \"Good Cholesterol\"", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dyslipidaemias" ], "interventions": [ { "name": "GW590735", "type": "DRUG" }, { "name": "fenofibrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2003-11", "completion_date": "2005-04", "has_results": false, "last_update_posted_date": "2012-10-22", "last_synced_at": "2026-10-28T08:16:50.181Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00169559" }, { "nct_id": "NCT01068782", "title": "Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Astrocytic Tumors" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2010-04", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-10-28T08:16:50.181Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Encinitas, California • Pleasant Hill, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Encinitas", "state": "California" }, { "city": "Pleasant Hill", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01068782" }, { "nct_id": "NCT00643890", "title": "Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Neurologix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "30 Years to 75 Years" }, "enrollment_count": 44, "start_date": "2008-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-02-22", "last_synced_at": "2026-10-28T08:16:50.181Z", "location_count": 7, "location_summary": "Stanford, California • Aurora, Colorado • Boston, Massachusetts + 4 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Southfield", "state": "Michigan" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00643890" } ] }